InnoCare Pharma

Dr. Jasmine Cui, Our Chairwoman and CEO, will join the 43rd Annual J.P. Morgan Healthcare Conference. We warmly welcome you to send below Email to schedule a meeting with our executives during #JPM25 to discuss our latest corporate development and potential cooperations. If you would like to explore BD opportunities, please contact BD@innocarepharma.com If you are an investor or analyst, you can contact IR@innocarepharma.com If you would like to interview our executives on site, please contact Chunhua Lu

Thanks for recognition from China's leading business media Southern Finance 南方财经全媒体 , our BTK inhibitor orelabrutinib won the award of Annual Excellent Innovative Drug due to its great market potential in the field of treatment of marginal zone lymphoma (MZL). Orelabrutinib has been approved as the first and only BTK inhibitor for r/r MZL in China.  #BTK #Innovation #orelabrutinib

Thanks for the recognition from Southern Weekly, our Chairwoman and CEO Dr. Jasmine Cui was awarded the "Science and Technology Innovation Leader" for her unique insights and outstanding innovation achievements. Meanwhile, she delivered a keynote speech titled "Focusing on New Quality Innovation and Leading the Development of Innovative Drug", sharing the latest innovation achievements of InnoCare Pharma and insights of the opportunities and challenges faced by the biopharma industry. #Innovation

More orelabrutinib studies presented at #2024ASH Preliminary Efficacy of Orelabrutinib Targeted Therapy in Induction Therapy of Primary Central Nervous System Diffuse B-Cell Lymphoma https://lnkd.in/eduKq9kh The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma https://lnkd.in/eJdmEknC Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Idiopathic Multicentric Castleman Disease: A Single-Center, Retrospective Study https://lnkd.in/emEX5aA6 https://lnkd.in/ePefm7cT

Here comes another three studies presented at the ongoing 2024 ASH. Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma https://lnkd.in/eUyXhev4 Preliminary Data of a Single-Arm, Phase II Study of Orelabrutinib with/without Rituximab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma after BTK Inhibitor Therapy https://lnkd.in/eJDyahpV Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring https://lnkd.in/gAQ4p2M5 https://lnkd.in/ePefm7cT #BTK #ASH

Latest data of BTKi orelabrutinib were presented at the ongoing 66th American Society of Hematology (ASH) Annual Meeting, including nine posters. Check more information: https://lnkd.in/ePefm7cT Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study https://lnkd.in/eD9cdwGa Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study) https://lnkd.in/e8R7NHqV A Prospective, Multicenter, Single-Arm Study on the Combination of Orelabrutinib and Rituximab in the Second-Line Treatment of Relapsed/Refractory Marginal Zone Lymphoma https://lnkd.in/eXCKMxCe #ASH #BTK

Welcome on board Susan Lin, MPH Let's make concerted efforts to accelerate our global trials to address unmet medical needs!

Happy Thanksgiving! Wishing you a wonderful thanksgiving filled with the health and warmth of the season! #thanksgiving

An in-depth article from DrugTimes analyzed the third quarter performance of InnoCare Pharma. Strong orelabrutinib growth, sharp loss decrease, and great potential of autoimmune pipelines…… Check more from the report: https://lnkd.in/eEYw2FMe

We just successfully held our 2024 R&D Day for #Investors , #Analysts and potential #BDPartners . Our management team and leading PIs shared their insights and key viewpoints, whose wonderful presentations demonstrated InnoCare Pharma robust pipeline in the field of autoimmune diseases and latest development of our BTKi and TYK2i for the treatment of #MultipleSclerosis #ImmuneThrombocytopenic #AtopicDermatitis and #Psoriasis respectively, all with huge unmet medical needs. Check more: https://lnkd.in/e7qxUUg7 https://lnkd.in/eTTce7Ez